Pathways Hospice Medicare Approved Location: 305 Carpenter Road, Fort Collins, Colorado 80525 Phone: (970) 663-3500 |
News Archive
vielife has received certification from the National Committee for Quality Assurance (NCQA) in the categories of health appraisals and self-management tools. This is the fourth consecutive time vielife has been awarded the certification.
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival hazard rates for women with recurrent epithelial ovarian cancer.
Ovarian cancer is the deadliest of all cancers affecting the female reproductive system with very few effective treatments available. Prognosis is even worse among patients with certain subtypes of the disease. Now, researchers at The Wistar Institute have identified a new therapeutic target in a particularly aggressive form of ovarian cancer, paving the way for what could be the first effective targeted therapy of its kind for the disease.
The University of New Hampshire will receive $1.8 million from the National Institutes of Health that will further molecular research to better understand drug interactions at the cellular level and help lead to the development of new targeted drugs to treat wide-spread metabolic, growth, neurological and visual disorders including diabetes and cancer.
› Verified 7 days ago